FC

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Retrieved on: 
Wednesday, February 14, 2024

AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.

Key Points: 
  • AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.
  • Fibrinogen, a plasma protein produced in the liver, plays a key role in stopping blood loss and in wound healing.
  • “The positive results for Biotest’s fibrinogen are an important milestone and strengthen a Grifols innovation strategy that’s diversified across plasma and non-plasma, balanced between internal and external investments, and includes both shorter- and longer-term development cycles,” said Victor Grifols Deu, Grifols Chief Operating Officer.
  • The acquisition of Biotest has significantly reinforced Grifols’ access to plasma, as well as the company’s pipeline and sales presence.

Automotive Fuel Cell Market worth $2.1 billion by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, February 12, 2024

Fuel Cell Hybrid Electric Vehicles (FCHEVs) have emerged as a promising solution in the automotive fuel cell industry , embodying a harmonious integration of fuel cell technology and secondary energy storage systems.

Key Points: 
  • Fuel Cell Hybrid Electric Vehicles (FCHEVs) have emerged as a promising solution in the automotive fuel cell industry , embodying a harmonious integration of fuel cell technology and secondary energy storage systems.
  • The fuel cell stack, a crucial fuel cell system component, consists of two flow field plates and a Membrane Electrode Assembly (MEA).
  • The fuel cell stack is considered the fuel cell system's most expensive component due to platinum's inclusion.
  • In October 2023, a 50kW fuel cell module (FC module) was developed by Toyota Motor, representing a compact fuel cell (FC) system.

Automotive Fuel Cell Market worth $2.1 billion by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, February 12, 2024

Fuel Cell Hybrid Electric Vehicles (FCHEVs) have emerged as a promising solution in the automotive fuel cell industry , embodying a harmonious integration of fuel cell technology and secondary energy storage systems.

Key Points: 
  • Fuel Cell Hybrid Electric Vehicles (FCHEVs) have emerged as a promising solution in the automotive fuel cell industry , embodying a harmonious integration of fuel cell technology and secondary energy storage systems.
  • The fuel cell stack, a crucial fuel cell system component, consists of two flow field plates and a Membrane Electrode Assembly (MEA).
  • The fuel cell stack is considered the fuel cell system's most expensive component due to platinum's inclusion.
  • In October 2023, a 50kW fuel cell module (FC module) was developed by Toyota Motor, representing a compact fuel cell (FC) system.

Nexon Releases Earnings for Fourth Quarter and Full-Year 2023

Retrieved on: 
Thursday, February 8, 2024

NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the financial results for its fourth quarter and fiscal year ended on December 31, 2023.

Key Points: 
  • NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced the financial results for its fourth quarter and fiscal year ended on December 31, 2023.
  • “Despite unforeseen short-term challenges in Q4, Nexon delivered record-setting full-year revenue and operating income in 2023, growing revenue 20% and operating income 30%,” said Owen Mahoney, President and CEO of Nexon.
  • The biggest of these is Dungeon&Fighter Mobile in China, which we plan to launch as soon as possible in 2024.
  • Nexon is working with our local publishing partner Tencent to launch the game as soon as possible in 2024.

Capital Rx Named to the 2024 New York Digital Health 100

Retrieved on: 
Thursday, February 8, 2024

NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Capital Rx , the full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA) advancing our nation's healthcare infrastructure to improve drug price visibility and patient outcomes, has been named to the 2024 New York Digital Health 100 (DH100) again.

Key Points: 
  • NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Capital Rx , the full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA) advancing our nation's healthcare infrastructure to improve drug price visibility and patient outcomes, has been named to the 2024 New York Digital Health 100 (DH100) again.
  • This recognition highlights the most exciting and innovative digital health companies in New York.
  • Digital Health New York (DHNY) publishes the annual list along with the New York Healthcare Innovation Report, which takes an in-depth look at the investment trends, opportunities, and challenges in the digital health sector.
  • "2024 marks the fifth year of the New York Digital Health 100, and in that time, the digital health ecosystem in New York has significantly grown and evolved," said Bunny Ellerin, Co-Founder and CEO of DHNY.

New York City FC and Capital Rx Announce Sleeve Partnership

Retrieved on: 
Tuesday, February 6, 2024

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Today, New York City FC (NYCFC) and Capital Rx , the health technology company committed to advancing our nation's healthcare infrastructure to improve drug price visibility and patient outcomes, are excited to announce Capital Rx as NYCFC's Official Sleeve Partner in a multi-year deal.

Key Points: 
  • NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Today, New York City FC (NYCFC) and Capital Rx , the health technology company committed to advancing our nation's healthcare infrastructure to improve drug price visibility and patient outcomes, are excited to announce Capital Rx as NYCFC's Official Sleeve Partner in a multi-year deal.
  • Capital Rx's partnership with NYCFC is a unique opportunity to positively impact the local community for years to come.
  • "We are excited to welcome a like-minded, New York company in Capital Rx as our new Official Sleeve Partner of New York City FC," said Brad Sims, NYCFC CEO.
  • "Both the Club and Capital Rx are mission-driven organizations that believe in using their platforms to champion healthier lives."

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

Retrieved on: 
Monday, February 5, 2024

Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® (tafasitamab-cxix) and outside of the U.S. as Minjuvi® (tafasitamab).

Key Points: 
  • Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® (tafasitamab-cxix) and outside of the U.S. as Minjuvi® (tafasitamab).
  • “This new agreement with MorphoSys provides Incyte with exclusive global rights to tafasitamab and full control over its development and commercialization, allowing us to realize significant operating efficiencies and cost synergies,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • In the previous agreement , MorphoSys and Incyte were collaborating and sharing costs for the clinical development and commercialization of tafasitamab in the U.S.; Incyte had exclusive rights outside of the U.S.
  • Under the terms of the new agreement, MorphoSys will receive a payment of $25 million from Incyte and Incyte will gain global development and commercialization rights for tafasitamab.

Chiyoda Corporation and Toyota Jointly Developing Large-scale Electrolysis System

Retrieved on: 
Monday, February 5, 2024

Toyota City, Japan, Feb 5, 2024 - (JCN Newswire) - Chiyoda Corporation and Toyota Motor Corporation have agreed to jointly develop a large-scale electrolysis system and construct a strategic partnership and have signed a basic agreement on cooperation.

Key Points: 
  • Toyota City, Japan, Feb 5, 2024 - (JCN Newswire) - Chiyoda Corporation and Toyota Motor Corporation have agreed to jointly develop a large-scale electrolysis system and construct a strategic partnership and have signed a basic agreement on cooperation.
  • The production and mass production technologies for electrolysis cell stacks using the fuel cell technology held by Toyota and the processing plant design technologies and large-scale plant construction technologies held by Chiyoda will be brought together to develop a large-scale electrolysis system that can be competitive.
  • Specifically, the goal is to develop an electrolysis system with high hydrogen production efficiency while being the world's smallest in size.
  • With the signing of this basic agreement on cooperation, the introduction of an electrolysis system in Hydrogen Park at the Toyota Honsha Plant will start in FY2025.

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Retrieved on: 
Wednesday, January 31, 2024

23andMe plans to evaluate ‘1473 in participants with advanced solid tumors in a Phase 1 clinical study beginning in the first half of 2024.

Key Points: 
  • 23andMe plans to evaluate ‘1473 in participants with advanced solid tumors in a Phase 1 clinical study beginning in the first half of 2024.
  • ‘1473 targets ULBP6 to restore anti-tumor immunity through NK and T cells.
  • Further, ‘1473 is Fc-effector enhanced, which provides an additional mechanism for NK cells to induce cell death of ULBP6-expressing cancer cells.
  • “This program further validates the 23andMe database as a proven resource for identifying novel therapeutic targets,” said Jennifer Low, Head of Therapeutics Development, 23andMe.

Electronic Arts Reports Strong Q3 FY24 Results

Retrieved on: 
Tuesday, January 30, 2024

(NASDAQ: EA) today announced preliminary financial results for its third quarter ended December 31, 2023.

Key Points: 
  • (NASDAQ: EA) today announced preliminary financial results for its third quarter ended December 31, 2023.
  • “Our incredible teams delivered a strong Q3, entertaining hundreds of millions of people across our portfolio, driving deep engagement and record live services,” said Andrew Wilson, CEO of EA.
  • Live services and other net bookings for Q3 achieved a record $1.712 billion, up 3% year-over-year (up 5% in constant currency).
  • The EA SPORTS FCTM franchise outperformed Q3 expectations, delivering 7% net bookings growth against a prior year that included the World Cup.